Flexion Therapeutics (NASDAQ:FLXN) issued its quarterly earnings results on Thursday. The specialty pharmaceutical company reported ($1.00) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.01) by $0.01, Fidelity Earnings reports. Flexion Therapeutics had a negative net margin of 368.31% and a negative return on equity of 175.29%. The business had revenue of $21.79 million for the quarter, compared to analysts’ expectations of $18.85 million.
Shares of NASDAQ FLXN traded down $0.69 during trading on Friday, hitting $16.43. 1,132,400 shares of the company traded hands, compared to its average volume of 622,178. Flexion Therapeutics has a fifty-two week low of $8.76 and a fifty-two week high of $17.82. The business’s fifty day moving average is $14.85 and its 200 day moving average is $12.36. The firm has a market capitalization of $655.05 million, a price-to-earnings ratio of -3.66 and a beta of 1.38. The company has a debt-to-equity ratio of 3.95, a quick ratio of 7.33 and a current ratio of 7.80.
Several brokerages have recently weighed in on FLXN. BidaskClub upgraded shares of Flexion Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, November 5th. Northland Securities set a $20.00 price objective on shares of Flexion Therapeutics and gave the company a “buy” rating in a report on Tuesday, September 10th. ValuEngine lowered shares of Flexion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, October 25th. Finally, Zacks Investment Research lowered shares of Flexion Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 8th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $23.57.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.
Featured Story: Rule of 72
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.